The global burden of lung cancer: current status and future trends

被引:0
|
作者
Amanda Leiter
Rajwanth R. Veluswamy
Juan P. Wisnivesky
机构
[1] Icahn School of Medicine at Mount Sinai,Division of Endocrinology, Diabetes, and Bone Diseases, Department of Medicine
[2] Icahn School of Medicine at Mount Sinai,Division of Hematology and Oncology, Department of Medicine
[3] Icahn School of Medicine at Mount Sinai,Division of General Internal Medicine, Department of Medicine
[4] Icahn School of Medicine at Mount Sinai,Tisch Cancer Institute
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Lung cancer is the leading cause of cancer-related death worldwide. However, lung cancer incidence and mortality rates differ substantially across the world, reflecting varying patterns of tobacco smoking, exposure to environmental risk factors and genetics. Tobacco smoking is the leading risk factor for lung cancer. Lung cancer incidence largely reflects trends in smoking patterns, which generally vary by sex and economic development. For this reason, tobacco control campaigns are a central part of global strategies designed to reduce lung cancer mortality. Environmental and occupational lung cancer risk factors, such as unprocessed biomass fuels, asbestos, arsenic and radon, can also contribute to lung cancer incidence in certain parts of the world. Over the past decade, large-cohort clinical studies have established that low-dose CT screening reduces lung cancer mortality, largely owing to increased diagnosis and treatment at earlier disease stages. These data have led to recommendations that individuals with a high risk of lung cancer undergo screening in several economically developed countries and increased implementation of screening worldwide. In this Review, we provide an overview of the global epidemiology of lung cancer. Lung cancer risk factors and global risk reduction efforts are also discussed. Finally, we summarize lung cancer screening policies and their implementation worldwide.
引用
收藏
页码:624 / 639
页数:15
相关论文
共 50 条
  • [41] Current status and future of lung transplantation
    Date, H
    [J]. INTERNAL MEDICINE, 2001, 40 (02) : 87 - 95
  • [42] Current status of CTCs as liquid biopsy in lung cancer and future directions
    Zhang, Zhuo
    Ramnath, Nithya
    Nagrath, Sunitha
    [J]. FRONTIERS IN ONCOLOGY, 2015, 5
  • [43] Current status and future of anti-angiogenic drugs in lung cancer
    Yan, Xuan
    Zhao, Zhangyan
    Tang, Haicheng
    [J]. CLINICAL AND EXPERIMENTAL MEDICINE, 2023, 23 (06) : 2009 - 2023
  • [44] Current status and future perspectives of bispecific antibodies in the treatment of lung cancer
    Wang Wanying
    Qiu Tianyu
    Li Fei
    Ren Shengxiang
    [J]. 中华医学杂志(英文版), 2023, 136 (04)
  • [45] Current status and future perspectives of bispecific antibodies in the treatment of lung cancer
    Wang, Wanying
    Qiu, Tianyu
    Li, Fei
    Ren, Shengxiang
    [J]. CHINESE MEDICAL JOURNAL, 2023, 136 (04) : 379 - 393
  • [46] Global trends in oral cancer burden and control
    Sankaranarayanan, R.
    [J]. ORAL ONCOLOGY, 2011, 47 : S1 - S1
  • [47] Immunotherapy and targeted therapy for lung cancer: Current status and future perspectives
    Zulfiqar, Bilal
    Farooq, Asim
    Kanwal, Shahzina
    Asghar, Kashif
    [J]. FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [48] Current status and future of anti-angiogenic drugs in lung cancer
    Xuan Yan
    Zhangyan Zhao
    Haicheng Tang
    [J]. Clinical and Experimental Medicine, 2023, 23 : 2009 - 2023
  • [49] Labelling of biopolymers: current status and future trends
    Bettmer, Joerg
    Karst, Uwe
    [J]. ANALYTICAL AND BIOANALYTICAL CHEMISTRY, 2010, 397 (08) : 3431 - 3432
  • [50] Thermal Spray: Current Status and Future Trends
    Herbert Herman
    Sanjay Sampath
    Robert McCune
    [J]. MRS Bulletin, 2000, 25 : 17 - 25